You are here: Industry Insights > Perrigo

News List

Perrigo Completes Divestiture Of Generic Rx Business For $1.55 Billion firstwordpharma
July 07, 2021
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has completed the previously announced sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion
Healthcare industry reported 119 deals worth $10.8 billion in March 2021 expresspharma
April 08, 2021
In March 2021, the healthcare industry reported 119 deals worth $10.8 billion as compared to the last 12-month average (March 2020 to February 2021) of 94 deals worth $20 billion.
Perrigo Voluntary Recalls Albuterol Inhaler americanpharmaceuticalreview
September 27, 2020
The U.S. Food and Drug Administration (FDA) is alerting health care professionals and patients of a voluntary recall of all unexpired albuterol sulfate inhalation aerosol manufactured by Catalent Pharma Solutions for Perrigo Pharmaceutical Company ...
Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray americanpharmaceuticalreview
August 23, 2019
Perrigo Company has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc. Terms of the settlement are confidential.
Could a 'creative deal' between Perrigo, Amneal help reinvent both struggling businesses? fiercepharma
August 22, 2019
With a spinoff for its prescription business on the ropes, Perrigo is treading water in its plans to reinvent its flagging business. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?
Irish authorities demand €1.6bn in back tax from Perrigo pharmaceutical-technology
December 24, 2018
The Irish tax authority Revenue Commissioners has issued a Notice of Amended Assessment (NoA) to Perrigo stating the company owes €1.64bn in tax from 2013 intellectual property sales by Elan Pharma, which was later acquired by Perrigo.....
Perrigo rejects Mylan's acquisition bid biospectrumasia
October 12, 2018
Perrigo rejects Mylan's acquisition bid
Perrigo plans separation of Rx business pharmaceutical-technology
August 14, 2018
Perrigo has announced plans to separate its Prescription Pharmaceuticals (Rx) business following a recent strategic portfolio review.
Perrigo to Separate Prescription Pharmaceuticals Business americanpharmaceuticalreview
August 13, 2018
Perrigo announced its Board of Directors approved a plan to separate the company's Prescription Pharmaceuticals (Rx) business following the company's previously announced strategic portfolio review......
Perrigo Expands OTC Growth Strategy with Licensing for Nasonex americanpharmaceuticalreview
August 10, 2018
Perrigo has entered into a licensing agreement with a subsidiary of Merck for the exclusive rights in the United States to pursue regulatory approval for a non-prescription, over-the-counter (OTC) Nasonex (mometasone furoate monohydrate) Nasal Spray.

Previous page 1 2 3 Next page